The upgrade to a Buy rating is based on Novo Nordisk's strong Q3 2024 results, which have alleviated previous concerns about Wegovy's sales. Additionally, the company's market multiples, including a forward P/E for 2025 at 28.3x, are now considered attractive, making the stock a more appealing investment.